Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
- PMID: 11286223
- DOI: 10.1182/blood.v97.7.2183
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
Comment on
-
Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.Blood. 1995 Oct 1;86(7):2815-20. Blood. 1995. PMID: 7670117 Clinical Trial.
-
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.Blood. 1999 Dec 15;94(12):4029-35. Blood. 1999. PMID: 10590046 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

